MetaCap

MAIA Biotechnology (MAIA) vs PMV Pharmaceuticals (PMVP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MAIA Biotechnology (MAIA) has outperformed PMV Pharmaceuticals (PMVP) over the past year, gaining 21.7% versus a loss of 33.6%. MAIA Biotechnology is the larger company by market cap ($68.5 million vs $66.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MAIA+21.71%PMVP-33.64%
+236%+95%-46%
Nov 21, 20251 yearNov 20, 2026
MAIA-80.86%PMVP-94.14%
+19%-40%-100%
Jul 25, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MAIA versus PMVP key metrics
MetricMAIAPMVP
Share price$1.11$0.876
Market cap$68.54M$66.17M
1-day change-2.63%-33.13%
YTD return-27.45%-29.92%
1-year return+21.71%-33.64%
5-year return—-96.22%
EPS (TTM)$-0.47$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-22.40M$-77.74M
52-week high$3.19$1.91
52-week low$0.895$0.66
Distance from 52-week high-65.20%-54.14%
Analyst consensusnonestrong_buy
Avg. price target upside+981.08%+356.62%
Average volume524.29K787.50K
Shares outstanding61.75M75.53M
Employees1354
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MAIA has outperformed PMVP by 55.3 percentage points over the past year.

About MAIA Biotechnology

MAIA stock →

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About PMV Pharmaceuticals

PMVP stock →

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees

MAIA vs PMVP FAQ

Which is bigger, MAIA Biotechnology or PMV Pharmaceuticals?

MAIA Biotechnology (MAIA) is larger, with a market capitalization of $68.54M compared with $66.17M for PMV Pharmaceuticals (PMVP).

Which stock has performed better over the past year, MAIA or PMVP?

MAIA returned +21.71% over the past 12 months, compared with -33.64% for PMVP (price return, excluding dividends). Past performance does not predict future results.

Are MAIA Biotechnology and PMV Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons